ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the [...] Read more »
Curia soutient l'essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d'ARN de nouvelle génération
ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan, a annonc aujourd'hui que son partenaire, Replicate [...] Read more »
Lifezone Metals Reports Completion of Tembo Zone Infill Drilling at the Kabanga Nickel Project with 41 m Intersect at 2.07% Ni, including 16.4 m at 2.77% Ni
New York (United States), Dar es Salaam (Tanzania), Aug. 31, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited ("Lifezone Metals" or the "Company") (NYSE: LZM), a modern metals company creating value [...] Read more »
Zenas BioPharma gibt die Veröffentlichung von Daten zu einer Phase-2-Studie mit Obexelimab, einem Prüfpräparat zur Behandlung der IgG4-assoziierten Erkrankung (IgG4-RD), im Fachjournal „The Lancet Rheumatology“ bekannt
Die Studie ergab, dass Obexelimab bei den meisten Patientinnen und Patienten mit aktiver IgG4–RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschlielich einer vollstndigen klinischen [...] Read more »
Zenas BioPharma annonce la publication d'une étude de phase 2 sur l'obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology
L'tude a montr que l'obxlimab produisait une amlioration clinique rapide, forte et soutenue, y compris une rmission clinique complte, chez la plupart des patients atteints de ML–IgG4 active
Read more »
Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology
Estudo revelou que o obexelimabe produziu melhora clnica rpida, forte e sustentada, incluindo remisso clnica completa, na maioria dos pacientes com IgG4–RD ativa
Os resultados apoiam o [...] Read more »
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4–RD
Results support the [...] Read more »
Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice
Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) — Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen iro colaborar no desenvolvimento e comercializao futuros de NRX–101 para tratar [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen Inc. kündigen Zusammenarbeit zur Entwicklung und Vermarktung von NRX-101 an
- NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen kooperieren bei der weiteren Entwicklung und Vermarktung von NRX–101 gegen [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen Inc. annoncent leur collaboration pour le développement et la commercialisation du NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen collaborent au dveloppement et la commercialisation sur les marchs mondiaux du [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX–101 for suicidal treatment–resistant bipolar depression (S–TRBD) for global markets
Read more »
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4–RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs
[...] Read more »Two Female Scientists Win this year’s King Faisal Prize
Jeddah, Saudi Arabia, Jan. 04, 2023 (GLOBE NEWSWIRE) — Two women scientists were announced King Faisal Prize for Medicine and Science laureates for 2023: a Covid–19 vaccine developer and a nanotechnology scientist. Six others [...] Read more »
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases
First in human clinical study provides proof–of–concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of [...] Read more »